SE0202886L - Dermatologisk användning och dermatologisk beredning - Google Patents

Dermatologisk användning och dermatologisk beredning

Info

Publication number
SE0202886L
SE0202886L SE0202886A SE0202886A SE0202886L SE 0202886 L SE0202886 L SE 0202886L SE 0202886 A SE0202886 A SE 0202886A SE 0202886 A SE0202886 A SE 0202886A SE 0202886 L SE0202886 L SE 0202886L
Authority
SE
Sweden
Prior art keywords
dermatological
preparation
triiodothyronine
thyroxine
thyroid hormone
Prior art date
Application number
SE0202886A
Other languages
Unknown language ( )
English (en)
Swedish (sv)
Other versions
SE0202886D0 (sv
Inventor
Pekka Heino
Original Assignee
Ipsat Therapies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsat Therapies Oy filed Critical Ipsat Therapies Oy
Publication of SE0202886D0 publication Critical patent/SE0202886D0/xx
Publication of SE0202886L publication Critical patent/SE0202886L/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
SE0202886A 2000-04-06 2002-10-01 Dermatologisk användning och dermatologisk beredning SE0202886L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20000818A FI107018B (fi) 2000-04-06 2000-04-06 Dermatologinen käyttö ja valmiste
PCT/FI2001/000100 WO2001076589A1 (en) 2000-04-06 2001-02-05 Dermatological use and a dermatological preparation

Publications (2)

Publication Number Publication Date
SE0202886D0 SE0202886D0 (sv) 2002-10-01
SE0202886L true SE0202886L (sv) 2002-12-02

Family

ID=8558139

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202886A SE0202886L (sv) 2000-04-06 2002-10-01 Dermatologisk användning och dermatologisk beredning

Country Status (14)

Country Link
US (2) US20030144359A1 (OSRAM)
EP (1) EP1274416A1 (OSRAM)
JP (1) JP2003530349A (OSRAM)
AU (1) AU2001235506A1 (OSRAM)
CA (1) CA2405425A1 (OSRAM)
CH (1) CH695983A5 (OSRAM)
DE (1) DE10196025T1 (OSRAM)
DK (1) DK200201483A (OSRAM)
ES (1) ES2193003B1 (OSRAM)
FI (1) FI107018B (OSRAM)
GB (1) GB2377380B (OSRAM)
NO (1) NO20024810L (OSRAM)
SE (1) SE0202886L (OSRAM)
WO (1) WO2001076589A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508241A (ja) * 1995-06-07 1999-07-21 カロ バイオ エービー 甲状腺ホルモンまたは甲状腺ホルモン様化合物に関する新規な使用
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
JP2007505837A (ja) * 2003-09-15 2007-03-15 オードウェイ リサーチ インスティテュート 甲状腺ホルモンアナログおよび新脈管形成における使用の方法
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
JP2010513526A (ja) 2006-12-22 2010-04-30 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド 甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
WO2010075332A1 (en) * 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB859546A (en) * 1956-05-29 1961-01-25 Arthur Alfred Hellbaum Composition for treatment of the skin
US3198702A (en) * 1960-03-17 1965-08-03 Arthur A Hellbaum Method for treating skin burns
CA2184002A1 (en) * 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
US6380255B1 (en) * 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
JPH11508241A (ja) * 1995-06-07 1999-07-21 カロ バイオ エービー 甲状腺ホルモンまたは甲状腺ホルモン様化合物に関する新規な使用
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine
US5951989A (en) * 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
EP1173163B1 (en) * 1999-04-26 2006-06-21 Elliot Danforth, Jr. Pharmaceutical compositions of tetrac and methods of use thereof
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels

Also Published As

Publication number Publication date
SE0202886D0 (sv) 2002-10-01
US20050272817A1 (en) 2005-12-08
US20030144359A1 (en) 2003-07-31
DE10196025T1 (de) 2003-03-13
DK200201483A (da) 2002-10-03
AU2001235506A1 (en) 2001-10-23
GB0222880D0 (en) 2002-11-13
ES2193003A1 (es) 2003-10-16
NO20024810L (no) 2002-12-06
EP1274416A1 (en) 2003-01-15
GB2377380A (en) 2003-01-15
JP2003530349A (ja) 2003-10-14
FI20000818A0 (fi) 2000-04-06
FI107018B (fi) 2001-05-31
ES2193003B1 (es) 2005-02-01
GB2377380B (en) 2004-07-14
CA2405425A1 (en) 2001-10-18
WO2001076589A1 (en) 2001-10-18
CH695983A5 (de) 2006-11-15
NO20024810D0 (no) 2002-10-04

Similar Documents

Publication Publication Date Title
SE0202886D0 (sv) Dermatological use and a dermatological preparation
EA200100934A1 (ru) Применение ингибиторов cyp2d6 в комбинированных способах лечения
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
ATE429947T1 (de) Vorrichtung zur topischen verabreichung
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
NO20020299D0 (no) Behandling og sammensetning for oppnåelse av antialdring av hud med Corneum Protease aktivering
ATE312635T1 (de) Ventilanordnung
NO20060416L (no) Ny anvendelse I
ES2192227T3 (es) Composiciones farmaceuticas orales con liberacion retardada de inhibidores reversibles de las bombas de protones.
ID27503A (id) Tts yang mengandung antioksidan
NO20023551D0 (no) Ibuprofen-inneholdende aktivt middel-preparat
MXPA03009224A (es) Tratamiento de diabetes tipo 2 con inhibidores de peptidasa de dipeptidilo iv.
ATE339224T1 (de) Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung
DK1383540T3 (da) Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
NO20052494D0 (no) Preparater inneholdende melatonin, gingko biloba og biotin.
UY26474A1 (es) Inhibidores de aminotransferasa dependiente de aminoácidos de cadena ramificada, y su uso en el tratamiento de la retinopatía diabética.
GB9903403D0 (en) Substituted stilbene compounds with vascular damaging activity
AR004052A1 (es) Una composición cosmética o farmacéutica que comprende un agonista beta-adrenergico
DK1414467T3 (da) Topisk behandling af mastalgi
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
IS2147B (is) Notkun á blöndu díóls og alfa-hýdroxýsýru til að meðhöndla sjúkdóma sem lýsa sér í ofvexti í hornlagi húðþekju
DK0994704T3 (da) Anvendelse af GABA-analoger såsom gabapentin i fremstillingen af et medikament til behandling af inflammatoriske sygdomme
SE9601527D0 (sv) Transdermally alministered acetylcysteine as mucolytic agent
ES2187156T3 (es) Terapia antidepresiva.
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака

Legal Events

Date Code Title Description
NAV Patent application has lapsed